CPI was an excellent partner, aiding in demonstrating the manufacturing feasibility of our top bacterial candidates and distinguishing between strains in co-cultures. Their facilities in Darlington were impressive, facilitating rapid data generation. We’re now collaborating with CPI again to complete our preclinical program and prepare for the launch of our symbiotic supplement. I am excited to see this hard work translate into improved health for the next generation of infants!

With CPI, we’ve shown that ambient-stable vaccine formulations are achievable, enabling global vaccine equity. CPI’s expertise, including proving the large-scale manufacturability of our TheraPHIX™ stabiliser, has advanced us far faster than we could have managed alone, giving us the credibility to aim for widespread adoption by vaccine manufacturers worldwide.

Thanks to the expertise in drug development and manufacture brought by the colleagues from Quay, CPI and Pharmidex, we successfully developed a scalable manufacturing process for oral antibody products.

With digital tools we can build in operational excellence right from the start of pharmaceutical development, improve product robustness, and drive more efficient manufacturing processes to deliver more medicines to more patients, more quickly.

CPI helped us accelerate a vital aspect of our manufacturing process to expedite our journey towards a clinical product. We’ve made significant progress in our GMP manufacturing capabilities, leading to our first DNA sales and increased interest in our products from partners and client base.

Manufacturing is just one part of the process, and CPI does so much more than just that. Growing mycolicibacteria consistently and reliably to food grade standard and combining them with other ingredients is difficult and requires attention to detail, expertise and experience from your partner.